You are here: Industry Insights > Regeneron

News List

AstraZeneca and Regeneron to Research, Develop and Commercialize Medicines for Obesity americanpharmaceuticalreview
July 28, 2021
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.
Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 prnewswire
July 21, 2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron's casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19.
Regeneron to invest $1.8bn to expand facilities in New York pharmaceutical-technology
July 19, 2021
Regeneron Pharmaceuticals has plans to invest nearly $1.8bn to boost research, preclinical production and support sites at its Westchester County campus in Tarrytown, New York, US.
Sanofi, Regeneron's Libtayo cleared for basal cell carcinoma pharmatimes
June 28, 2021
Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) has won a green light in Europe as the first immunotherapy to treat adults with locally advanced or metastatic basal cell carcinoma (BCC).
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) firstwordpharma
June 28, 2021
NTLA and REGN today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
Antibody cocktail improves survival in seronegative hospitalised COVID-19 patients europeanpharmaceuticalreview
June 18, 2021
Phase III data shows REGEN-COV™ (casirivimab and imdevimab) reduced risk of death by 20 percent in hospitalised COVID-19 patients lacking an immune response to SARS-CoV-2.
REGEN-COV Phase 3 Trial Meets Primary Outcome contractpharma
June 17, 2021
Improves survival by 20% in hospitalized COVID-19 patients lacking an immune response to SARS-CoV-2.
FDA Authorizes Lower Intravenous and Subcutaneous Dose of REGEN-COV™ Antibody Cocktail to Treat Patients with COVID-19 americanpharmaceuticalreview
June 09, 2021
Regeneron Pharmaceuticals Inc. announced the U.S. FDA updated the Emergency Use Authorization (EUA) for REGEN-COV™, lowering the dose to 1,200 mg (600 mg casirivimab and 600 mg imdevimab), which is half the dose originally authorized.
FDA updates Regeneron’s Covid-19 antibody EUA to lower dose pharmaceutical-technology
June 07, 2021
The US Food and Drug Administration (FDA) has updated the Emergency Use Authorization (EUA) for Regeneron Pharmaceuticals’ Covid-19 antibody cocktail, REGEN-COV, reducing the dose to 1,200mg from 2,400mg.
REGEN-COV™ antibody cocktail reduces hospitalisation or death by 70 percent europeanpharmaceuticalreview
March 24, 2021
Phase III data shows treatment with REGEN-COV™ (casirivimab and imdevimab) significantly reduces the risk of high-risk COVID-19 infected outpatients being hospitalised or dying.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page